Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent

被引:15
|
作者
Powell, Jason [1 ,2 ]
Taylor, James [1 ]
Garland, Scott G. [1 ,2 ]
机构
[1] Univ Florida, Coll Pharm, Gainesville, FL USA
[2] Univ Florida, Coll Med, Gainesville, FL USA
关键词
andexanet alfa; anticoagulation; direct oral anticoagulant;
D O I
10.1177/1060028019835209
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The purpose of this article is to review the available clinical trial data for andexanet alfa and its role in clinical practice. Data Sources: A MEDLINE/PubMed search was conducted (January 2000 to January 2019) using the keyword andexanet alfa for clinical trials. References of identified articles were searched by hand for additional citations. Study Selection and Data Extraction: We included English-language articles related to the Food and Drug Administration (FDA) approval of andexanet alfa or provided novel information regarding this drug entity. Data Synthesis: The findings of the review show that andexanet alfa may be a safe and effective option for the reversal of apixaban and rivaroxaban. Relevance to Patient Care and Clinical Practice: With the approval of this reversal agent, patients and providers can feel safer when using apixaban and rivaroxaban, which in turn may increase the use of these anticoagulant agents. Conclusions: The new FDA approval of andexanet alfa will allow safer use of oral anticoagulants and will likely further the use of direct oral anticoagulants for anticoagulant needs. Reversing enoxaparin-/edoxaban-induced bleeding with this agent should be limited because there is no FDA approval owing to the fact that only phase II trial data available.
引用
收藏
页码:940 / 946
页数:7
相关论文
共 50 条
  • [1] Comment: Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent
    Gilbert, Brian W.
    Reeder, Jacob A.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (11) : 1167 - 1167
  • [2] Andexanet Alfa for Factor Xa Inhibitor Reversal
    Wang, Josh J.
    Gosselin, Sophie
    Villeneuve, Eric
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (25): : 2498 - 2498
  • [3] Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
    Siegal, Deborah M.
    Curnutte, John T.
    Connolly, Stuart J.
    Lu, Genmin
    Conley, Pamela B.
    Wiens, Brian L.
    Mathur, Vandana S.
    Castillo, Janice
    Bronson, Michele D.
    Leeds, Janet M.
    Mar, Florie A.
    Gold, Alex
    Crowther, Mark A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25): : 2413 - 2424
  • [4] Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation
    Ghadimi, Kamrouz
    Dombrowski, Keith E.
    Levy, Jerrold H.
    Welsby, Ian J.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (02) : 115 - 122
  • [5] Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
    Carpenter, Elise
    Singh, Divita
    Dietrich, Eric
    Gums, John
    [J]. THERAPEUTIC ADVANCES IN DRUG SAFETY, 2019, 10
  • [6] Andexanet alfa for the reversal of factor Xa inhibitors
    Favresse, J.
    Hardy, M.
    van Dievoet, M. A.
    Sennesael, A. L.
    Douxfils, J.
    Samama, C. M.
    Vornicu, O.
    Dincq, A. S.
    Lessire, S.
    Mullier, F.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (05) : 387 - 397
  • [7] Andexanet Alfa Use in Cardiac Surgical Patients: A Xa Inhibitor and Heparin Reversal Agent
    Levy, Jerrold H.
    Connors, Jean M.
    [J]. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2021, 35 (01) : 265 - 266
  • [8] Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa
    Nederpelt, Charlie J.
    Naar, Leon
    Sylvester, Katelyn W.
    Barra, Megan E.
    Roberts, Russel J.
    Velmahos, George C.
    Kaafarani, Haytham M. A.
    Rosenthal, Martin G.
    King, David R.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (10) : 2532 - 2541
  • [9] Andexanet Alfa for Factor Xa Inhibitor-Associated Intracerebral Hemorrhage Does a Specific Reversal Agent Justify Its Cost?
    Patel, Nikhil
    Morris, Nicholas A.
    [J]. NEUROLOGY, 2021, 97 (21) : 971 - 972
  • [10] Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence
    Abdulrehman, Jameel
    Eikelboom, John W.
    Siegal, Deborah M.
    [J]. FUTURE CARDIOLOGY, 2019, 15 (06) : 395 - 404